RECRUITING

Magnetic Resonance & Optical Spectroscopy Validation

Conditions

Validation Studies Magnetic Resonance Spectroscopy Adenosine Triphosphate Validation Optical Spectroscopy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop and refine techniques for using magnetic resonance and optical spectroscopy to investigate how your body uses energy.

Official Title

Development and Validation of 31P Magnetic Resonance and Optical Spectroscopy for the Characterization of ATP in Whole Body Human Applications

Quick Facts

Study Start:2013-03

Study Completion:2024-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT01827527

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Male or female * Age 18 - 89 * Healthy (self assessed) * Weight under 350lbs * Able to walk 50 yards without stopping * Able to travel to hospital for study visits * Able to follow a 3-step command * Able to remain in magnetic resonance (MR) scanner for up to 2 hours	* Have internal metal medical devices, including cardiac pacemakers, aortic or cerebral aneurysm clips, artificial heart valves, ferromagnetic implants, shrapnel, wire sutures, joint replacements, bone or joint pins/rods/screws, metal fragments in your eye, or non-removable jewelry such as rings. * Are unwilling or unable to complete the imaging procedures for the duration of the magnetic resonance imaging (MRI) scan due to claustrophobia or other reason. * Serious mental illness that might preclude subject's ability to comply with study treatment * Are pregnant or plan on becoming pregnant in the next 8 weeks. * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) * Varicose Veins * Known genetic factor (Factor V Leiden, etc.) or hypercoagulable state, including cancer, leukemia - such as chronic myelocytic leukemia (CML), hemoglobinopathies - such as sickle-cell disease and multiple myeloma and other proteinopathies. * Diagnosed peripheral arterial or vascular disease * Family history of primary DVT or PE * Peripheral neuropathy * History of chronic venous stasis or lower extremity edema * Female taking hormonal birth control (oral or otherwise) AND smoker

Inclusion Criteria

Exclusion Criteria

* Male or female
* Age 18 - 89
* Healthy (self assessed)
* Weight under 350lbs
* Able to walk 50 yards without stopping
* Able to travel to hospital for study visits
* Able to follow a 3-step command
* Able to remain in magnetic resonance (MR) scanner for up to 2 hours

* Have internal metal medical devices, including cardiac pacemakers, aortic or cerebral aneurysm clips, artificial heart valves, ferromagnetic implants, shrapnel, wire sutures, joint replacements, bone or joint pins/rods/screws, metal fragments in your eye, or non-removable jewelry such as rings.
* Are unwilling or unable to complete the imaging procedures for the duration of the magnetic resonance imaging (MRI) scan due to claustrophobia or other reason.
* Serious mental illness that might preclude subject's ability to comply with study treatment
* Are pregnant or plan on becoming pregnant in the next 8 weeks.
* History of deep vein thrombosis (DVT) or pulmonary embolism (PE)
* Varicose Veins
* Known genetic factor (Factor V Leiden, etc.) or hypercoagulable state, including cancer, leukemia - such as chronic myelocytic leukemia (CML), hemoglobinopathies - such as sickle-cell disease and multiple myeloma and other proteinopathies.
* Diagnosed peripheral arterial or vascular disease
* Family history of primary DVT or PE
* Peripheral neuropathy
* History of chronic venous stasis or lower extremity edema
* Female taking hormonal birth control (oral or otherwise) AND smoker

Contacts and Locations

Study Contact

Recruitment Department

CONTACT

(407) 303-7100

tri@flhosp.org

Principal Investigator

Steven R. Smith, MD

PRINCIPAL_INVESTIGATOR

Translational Research Institute for Metabolism and Diabetes

Heather Cornnell, PhD

PRINCIPAL_INVESTIGATOR

Translational Research Institute for Metabolism and Diabetes

Study Locations (Sites)

Translational Research Institute for Metabolism and Diabetes

Orlando, Florida, 32804

United States

Collaborators and Investigators

Sponsor: AdventHealth Translational Research Institute

Steven R. Smith, MD, PRINCIPAL_INVESTIGATOR, Translational Research Institute for Metabolism and Diabetes
Heather Cornnell, PhD, PRINCIPAL_INVESTIGATOR, Translational Research Institute for Metabolism and Diabetes

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2013-03

Study Completion Date2024-12

Study Record Updates

Study Start Date2013-03

Study Completion Date2024-12

Terms related to this study

Keywords Provided by Researchers

Adenosine Triphosphate
Validation
Magnetic Resonance Spectroscopy
Optical Spectroscopy

Additional Relevant MeSH Terms

Validation Studies
Magnetic Resonance Spectroscopy